Farmas USA

HZNP

Pienso igual, espero recuperación mañana y pegarle un pellizco,,,,

HZNP

Pues no se si soy un suicida o no, pero acabo de comprar a 10,30$ y bajo mi media a 13,20$.

Ahora esperar que se recupere y al menos salir plano.

KERS

Estas me estan al menos dando una alegria. Aunque no llevo tanto como otras veces, por diversificar algo y meterlo en HZNP. 

dentro a 10,07 voy con vosotros

HZNP

HZNP

Añado más a 10.14

Novavax (NASDAQ: NVAX): Q1 EPS of -$0.16 beats by $0.01.

Revenue of $5.68M (+34.6% Y/Y) misses by $0.49M.

First Quarter Achievements:

• Enrollment continued during the second global season in the RSV Phase 3 PrepareTM clinical trial for infants via maternal immunization. Enrollment in the first quarter of 2017 transitioned from the northern hemisphere to southern hemisphere sites in Argentina, Australia, Chile, New Zealand and South Africa. The second season of enrollment has benefitted greatly from the establishment of the operational infrastructure and experience from the first global season, resulting in material increases in enrollment and enhanced momentum as we move towards the third global season of enrollment.
• Initiation of a randomized, observer-blinded, multi-arm, dose-ranging Phase 2 clinical trial, in one and two dose formulations, both with and without adjuvants, of its RSV F Vaccine in older adults (60 years of age and older). The trial will evaluate safety and immunogenicity of these formulations in older adults as measured by serum microneutralization titers against RSV/A and RSV/B, palivizumab competing antibodies ("PCA") and anti-F IgG.

Anticipated 2017 Events:

• Announce top-line data from the Phase 2 safety and immunogenicity clinical trial of the RSV F vaccine in older adults in the next 90 days.
• File revised study documents and conduct an informational analysis of the Prepare trial that would provide an indication of the RSV F Vaccine's potential efficacy against the trial's primary endpoint before the end of the year.
• Initiate a Phase 1 clinical trial of the Company's recombinant seasonal influenza vaccine candidate before the end of the year.
• Initiate a Phase 1 clinical trial of the Company's Zika vaccine candidate before the end of the year.

Summary

"We continued to make significant progress in the execution of our two key clinical trials of our RSV F vaccine for both infant via maternal immunization and in older adults. We look forward to reporting important clinical data from our older adult trial in the next 90 days. We've also been in discussion with the FDA about conducting an informational analysis of the Prepare trial that would provide an indication of our vaccine's potential efficacy. From these discussions, we believe we can conduct this analysis in late 2017," said Stanley C. Erck, President and CEO. "In addition, we are seeing the continued adoption and use of our proprietary adjuvant, Matrix-M, in a number of internal and partnered programs."

Financial Results for the Three Months Ended March 31, 2017

Novavax reported a net loss of $43.9 million, or $0.16 per share, for the first quarter of 2017, compared to a net loss of $77.3 million, or $0.29 per share, for the first quarter of 2016.

Novavax revenue in the first quarter of 2017 increased 35% to $5.7 million, compared to $4.2 million for the same period in 2016, primarily due to increased revenue recorded under the BMGF grant relating to our ongoing Prepare clinical trial.

Research and development expenses decreased 45% to $37.7 million in the first quarter of 2017, compared to $69.0 million for the same period in 2016. The decrease was primarily due to reduced costs associated with the clinical trials and development activities of our RSV F Vaccine and lower employee-related costs.

General and administrative expenses decreased 16% to $8.9 million in the first quarter of 2017, compared to $10.5 million for the same period in 2016. The decrease was primarily due to lower professional fees for pre-commercialization activities.

Interest income (expense), net for the first quarter of 2017 was ($3.0) million, compared to ($1.9) million for the same period in 2016.

As of March 31, 2017, the company had $211.2 million in cash and cash equivalents and marketable securities compared to $235.5 million as of December 31, 2016. Net cash used in operating activities for the first quarter of 2017 was $38.6 million, compared to $69.8 million for same period in 2016. The decrease in cash usage was primarily due to decreased costs relating to our RSV F Vaccine and lower employee-related costs.

Simplifico el semanal de HZNP

joer que dia ...

IBB

IBB EL selloff ha sido en parte porque sta semana se reunen lideres de biotechs con Trump y hay incertidumbre. Además tampoco ha ayudado la noticia de que un paciente ha muerto en el ensayo de CAR-T en KITE (ya pasó con JUNO).

Pregunta sin ánimo de ofender, porqué teneis todos en ete foro tanto interés en HZNP? No la sigo pero veo que muchos estais comprados o acabais de comprar. Si ayer dió un report de que ha tenido unas ventas horribles, que es lo que os interesa de esta?